Last updated: February 19, 2026
This report analyzes Australian patent application AU2005264864, specifically focusing on its claimed scope, the asserted patent landscape, and potential implications for pharmaceutical R&D and investment. The patent application, filed on October 28, 2005, by BAXTER INTERNATIONAL INC., concerns certain aspects of fluid infusion systems, with potential relevance to drug delivery.
What is the Core Technology Protected by AU2005264864?
The patent application AU2005264864 primarily describes and claims a fluid infusion system. The core technology revolves around an apparatus and method for delivering fluid from a primary container to a secondary container or directly to a patient. Key features include a connector assembly designed to facilitate sterile fluid transfer.
The described system aims to mitigate contamination risks during fluid exchange between containers, a critical factor in pharmaceutical compounding and administration. The application details various embodiments of the connector, including specific designs for septa, housings, and sealing mechanisms.
What Are the Key Claims of AU2005264864?
The claims of AU2005264864 define the legal boundaries of the invention. These claims dictate what specific aspects of the technology are protected and can be asserted against infringers.
Independent Claims
-
Claim 1: This independent claim broadly defines an apparatus for transferring fluid from a primary container to a secondary container. It specifies a primary connector attached to the primary container, a secondary connector attached to the secondary container, and a transfer line connecting the two. Crucially, it includes features that enable a closed system during fluid transfer, minimizing exposure to the environment. This involves a mechanism to maintain sterility when the connectors are detached and reattached.
-
Claim 2: This independent claim focuses on a method of transferring fluid. It outlines steps for connecting a primary container to a secondary container using the aforementioned connector system, transferring the fluid, and then disconnecting the containers while maintaining a sterile interface.
Dependent Claims
Dependent claims further refine and narrow the scope of the independent claims by adding specific limitations or preferred embodiments. These include:
-
Specific Connector Designs: Dependent claims detail particular configurations of the primary and secondary connectors. This can include the type of sealing mechanisms (e.g., O-rings, gaskets), the materials used, and the specific geometries of mating surfaces designed to ensure a secure and sterile seal. For instance, specific features for preventing backflow or air ingress are often detailed.
-
Transfer Line Configurations: Claims may specify the length, material, or internal diameter of the transfer line used to connect the primary and secondary containers.
-
Sterility Maintenance: Dependent claims often elaborate on the mechanisms by which sterility is maintained throughout the fluid transfer process. This might involve details about how the connectors are designed to self-seal or to be shielded from contamination when disconnected.
-
Container Types: The claims may specify the types of primary and secondary containers for which the system is intended, such as bags, bottles, or vials.
The precise wording of each claim is critical. For example, the definition of a "closed system" or the specific requirements for "sterility" can significantly impact the scope and enforceability of the patent.
What is the Patent Landscape Surrounding AU2005264864?
The patent landscape for fluid infusion and drug delivery systems is highly competitive, with numerous patents protecting various aspects of connectors, tubing, pumps, and administration sets. AU2005264864 is situated within this broader technological domain.
Key Competitors and Technologies
Companies such as Becton, Dickinson and Company (BD), Fresenius Medical Care, Teleflex Medical, and ICU Medical have extensive patent portfolios covering related technologies. These patents often address:
- Luer Lock and Other Connector Standards: Standardized connectors that ensure compatibility between different medical devices.
- Needle-Free Connectors: Devices designed to reduce the risk of needlestick injuries and associated infections.
- Closed System Transfer Devices (CSTDs): Devices specifically designed to prevent the escape of hazardous drug aerosols or droplets, and to prevent the entry of environmental contaminants. AU2005264864 appears to address aspects of this category.
- Infusion Pumps and Controllers: Devices that regulate the rate and volume of fluid delivery.
Prior Art Considerations
The novelty and inventiveness of AU2005264864 would have been assessed against prior art, which includes existing patents, publications, and publicly available technologies. Any publicly disclosed fluid infusion system with similar features predating the priority date of the application (October 28, 2005) could potentially invalidate the patent claims.
The strength of AU2005264864 depends on how distinct its claimed features are from existing technologies. If its claimed connectors or methods offer a significant improvement in sterility, ease of use, or cost-effectiveness compared to prior art, it is more likely to be considered valid and enforceable.
Potential Infringement and Freedom to Operate
For companies developing or marketing fluid infusion systems, particularly those involving sterile drug transfer, a freedom-to-operate (FTO) analysis is essential. This involves assessing whether their products infringe upon existing patents, including AU2005264864.
The scope of the claims in AU2005264864 will determine which competing technologies or products might be considered infringing. If the patent is granted and remains in force, any company producing or selling fluid infusion systems that incorporate the claimed features without a license could face infringement lawsuits.
Patent Prosecution History
The prosecution history of AU2005264864, including any office actions from IP Australia and the applicant's responses, provides insights into how the claims were narrowed or amended during examination. This history can reveal examiner objections related to prior art and the applicant's arguments for patentability. Analyzing this history can help in understanding the interpreted scope of the claims.
What Are the Implications for Pharmaceutical R&D and Investment?
The patent AU2005264864, if granted, has direct implications for pharmaceutical companies involved in drug formulation, compounding, and delivery.
Drug Formulation and Compounding
Pharmaceutical manufacturers developing injectable drugs that require sterile reconstitution or dilution would need to consider the limitations imposed by this patent. If the patented connector system is crucial for maintaining drug integrity and sterility during the compounding process, then access to this technology might require licensing from BAXTER INTERNATIONAL INC.
The patent's focus on a closed system for fluid transfer is particularly relevant for the preparation of cytotoxic drugs, biologics, and other sensitive pharmaceuticals where environmental contamination poses a significant risk to patient safety and product efficacy.
Drug Delivery Devices
Companies designing or manufacturing drug delivery devices, such as pre-filled syringes, infusion bags with integrated connectors, or automated compounding systems, must conduct thorough FTO analyses. The claims of AU2005264864 could impact the design and functionality of such devices.
If a new drug requires a specific type of sterile connection for administration, and that connection falls within the scope of the patent, it could necessitate either designing around the patent, licensing the technology, or challenging the patent's validity.
Investment Decisions
For investors, understanding the IP landscape surrounding drug delivery technologies is crucial. Patents like AU2005264864 can create barriers to entry or create licensing revenue streams.
- Licensing Opportunities: If BAXTER INTERNATIONAL INC. actively licenses this technology, it presents an investment opportunity in a potentially revenue-generating patent.
- Competitive Advantage: Companies that hold or have secured licenses for such patented technologies may gain a competitive advantage in the market for sterile drug delivery.
- Risk Assessment: For companies in the drug delivery space, the existence of this patent, or similar patents, represents a risk that needs to be managed through FTO assessments and potential legal challenges or licensing negotiations.
The commercial success of drugs that rely on specific sterile fluid transfer methods could be significantly influenced by the intellectual property rights associated with those methods. Therefore, a detailed understanding of patents like AU2005264864 is integral to strategic R&D planning and investment decisions in the pharmaceutical and medical device sectors.
Key Takeaways
- AU2005264864 describes and claims a fluid infusion system with an emphasis on sterile fluid transfer between containers, utilizing specific connector assemblies.
- The patent's claims focus on the apparatus and method for creating a closed system to maintain sterility during fluid exchange.
- The patent landscape for fluid infusion and drug delivery is crowded, with significant IP held by major medical device manufacturers.
- Companies developing sterile drug compounding and delivery systems must conduct FTO analyses to avoid infringement of AU2005264864 and similar patents.
- The patent could impact drug formulation, the design of drug delivery devices, and investment strategies in the pharmaceutical and medical device industries.
Frequently Asked Questions
-
What is the priority date for AU2005264864?
The priority date for AU2005264864 is October 28, 2005.
-
What type of fluid is the patent application primarily concerned with?
While not explicitly limited to a single type of fluid, the application's focus on sterile transfer and contamination prevention is highly relevant for pharmaceutical preparations, including injectable drugs, chemotherapy agents, and biologics.
-
Does AU2005264864 protect the drugs themselves, or the delivery system?
This patent application protects aspects of the fluid infusion system and the method of fluid transfer, not the pharmaceutical drugs themselves.
-
Is AU2005264864 currently a granted patent in Australia?
As of the available information, AU2005264864 is an application. Its granted status as a patent would require checking the Australian Patent Register for its current status.
-
What are the key advantages claimed for the system described in AU2005264864 over existing methods?
The primary advantages appear to be the maintenance of a sterile, closed system during fluid transfer, thereby minimizing the risk of environmental contamination of the fluid and preventing the escape of hazardous substances from the system.
Cited Sources
[1] BAXTER INTERNATIONAL INC. (2005). Fluid infusion system. Australian Patent Application AU2005264864.
